Merck announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes…. 

Researchers report that, for type 1 diabetes patients who have good glycemic control, renal function may predict their risk of developing heart disease….

Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes…. Boehringer Ingelheim and Eli Lilly announced data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) …

First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …

Researchers have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects…. 

Eli Lilly and Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes…. 

The use of an outpatient electronic health record (EHR) system, rolled out across 17 medical centers, was associated with improvements in clinical outcomes and health care utilization in a study population of nearly 170,000 people with diabetes…. 

Kidney disease is a significant predictor of all-cause mortality and end-stage renal disease (ESRD) in patients with and without hypertension or diabetes, according to two large meta-analyses…. 

Insulin degludec, an investigational insulin with a prolonged half-life and a reportedly flatter pharmacokinetic profile with fewer high and low levels, showed a modest hypoglycemic edge over insulin glargine in a 52-week head-to-head comparison in patients with type 2 diabetes….

We are all aware of the problems which can occur when our patients take too much insulin or sulfonylureas, potentially leading to dangerously low blood glucose levels. But can you imagine that a diabetes patient could end up beaten and in jail because of hypoglycemia caused by a non-diabetes medication? …